Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seville
Clinical trial register · Spain

Clinical Trials in Seville, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca71 Hoffmann-La Roche48 Merck Sharp & Dohme LLC47 Janssen Research & Development, LLC40 Eli Lilly and Company37
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Seville

1054 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia
2024-04-09
Active, closed
Amgen
Phase 3
434
Córdoba, Bilbao, A Coruña, Madrid, San Cristóbal de La Laguna, Santa Coloma de Gramenet(Barcelona), Seville, Vitoria-Gasteiz
2024-04-08
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz
2024-04-03
Recruiting
Hoffmann-La Roche
Phase 4
320
Madrid, Seville, Valencia
2024-04-02
Active, closed
Novo Nordisk A/S
Phase 3
673
Castilleja de la Cuesta, Salamanca, Majadahonda, Madrid, Sanlúcar de Barrameda, Santiago de Compostela, Seville, Valencia
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
A Coruña, Alcalá de Henares, Lleida, Madrid, Málaga, Murcia, Oviedo, Seville
2024-03-29
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
Badalona, Pozuelo de Alarcón, Madrid, Barcelona, Seville
2024-03-28
Active, closed
Gilead Sciences
Phase 2
228
Ferrol, Huelva, Santa Cruz de Tenerife, Seville, Valencia
2024-03-27
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Barcelona, Madrid, Málaga, Seville, Valencia
2024-03-25
Active, closed
Gilead Sciences
Phase 3
577
Badalona Barcelona, Barcelona, Madrid, Seville, Valencia
2024-03-25
Active, closed
AbbVie
Phase 2
156
Santiago de Compostela, Pamplona, Madrid, Seville
2024-03-23
Recruiting
Fundación Española de Hematología y Hemoterapía
Observational
300
Seville, L'Hospitalet de Llobregat, Barcelona, Guadalajara, Madrid, Murcia, Valencia
2024-03-22
Recruiting
University of Seville
Not applicable
34
Seville, Morón de la Frontera
2024-03-20
Recruiting
SOLTI Breast Cancer Research Group
Phase 2
50
Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia
2024-03-15
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia
2024-03-12
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia
2024-03-12
Recruiting
Instituto de Investigación Biomédica de Salamanca
Phase 1/2
27
Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville
2024-03-11
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Alcorcón, Badalona, Barcelona, Manises, Salamanca, Santiago de Compostela, Seville, Villajoyosa
2024-03-09
Active, closed
AbbVie
Phase 1
152
Barcelona, Madrid, Seville
2024-03-08
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Barcelona, Madrid, Seville
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Barcelona, Madrid, Ourense, Santander, Seville
2024-03-04
Recruiting
Takeda
Phase 3
50
Seville
2024-03-01
Active, closed
Sanofi
Phase 3
464
Badalona, Majadahonda, Seville, Alicante, Madrid
2024-02-29
Active, closed
Acumen Pharmaceuticals
Phase 2
542
Sant Cugat del Vallès, Cuarte de Huerva, Barcelona, Donostia / San Sebastian, Getxo, Madrid, Seville, Valencia
2024-02-29
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Barcelona, Madrid, Málaga, Seville, Valencia
2024-02-26
Recruiting
Kura Oncology, Inc.
Phase 1
171
Barcelona, Oviedo, Seville, Valencia
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda
2024-02-20
Active, closed
Pfizer
Phase 1/2
71
Barcelona, Lleida, Madrid, Seville
2024-02-19
Active, closed
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Madrid, Seville
2024-02-19
Active, closed
Janssen Research & Development, LLC
Phase 2
305
A Coruña, Alicante, Barcelona, Jaén, Lugo, Madrid, Málaga, Seville
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 1
46
Madrid, Seville, Valencia
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 3
428
A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia
2024-02-09
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia
2024-02-01
Recruiting
CarThera
Phase 3
560
Barcelona, Madrid, Seville
2024-01-29
Active, closed
AbbVie
Observational
427
Santiago de Compostela, Elche, Majadahonda, Granada, Madrid, Seville
2024-01-24
Active, closed
Sanofi
Phase 3
260
Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia
2024-01-23
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Barcelona, Madrid, Seville, Valencia, Málaga, Pozuelo de Alarcón
2024-01-23
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville
2024-01-18
Active, closed
International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures
NCT06097559Infertility of Uterine Origin, Implantation Failure
Igenomix
Observational
738
Madrid, Marbella, Málaga, Seville, Valladolid
2024-01-16
Active, closed
AbbVie
Phase 2/3
89
Santander, Majadahonda, Barcelona, Córdoba, Madrid, Seville, Zaragoza
2024-01-11
Active, closed
RZ358 Treatment for Congenital Hyperinsulinism
NCT06208215Congenital Hyperinsulinism
Rezolute
Phase 3
56
Barcelona, Seville
2024-01-11
Recruiting
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Phase 2
75
Pozuelo de Alarcón, A Coruña, Madrid, Málaga, Seville, Valencia
2024-01-11
Recruiting
Ryvu Therapeutics SA
Phase 2
98
Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia
2024-01-05
Active, closed
BioMarin Pharmaceutical
Phase 1/2
18
Barcelona, Seville
2024-01-03
Recruiting
Using Technologies to Promote HEalthy Lifestyles in Adolescents With Intellectual Disabilities
NCT07101523Intellectual Disabilities (F70-F79), Down Syndrome (DS), Autism Disorder
University of Seville
Not applicable
60
Seville
2024-01-01
Recruiting
University of Seville
Not applicable
4
Seville
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Jerez de la Frontera, Madrid, Ourense, Valencia, Lugo, Seville
2023-12-31
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Barcelona, Madrid, Santiago de Compostela, Seville
2023-12-28
Active, closed
Bristol-Myers Squibb
Phase 3
190
A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia
2023-12-21
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Barcelona, Madrid, Seville
2023-12-20
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
Barcelona, Vigo, Valencia, Madrid, Oviedo, Seville
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Murcia, Barcelona, Barakaldo, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Pontevedra, Seville, Córdoba
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Santiago de Compostela, Seville, Palma, Badalona, Sabadell, Terrassa, Santander, A Coruña
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón
2023-12-12
Active, closed
Sanofi
Phase 2
197
Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Sabadell, Madrid, Pamplona, Barcelona, Seville, Valencia
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
L'Hospitalet de Llobregat, Pozuelo de Alarcón, Majadahonda, Málaga, Barcelona, Seville
2023-12-06
Active, closed
Aura Biosciences
Phase 3
108
Barcelona, Santiago de Compostela, Seville, Valencia
2023-12-06
Active, closed
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
DrugPembrolizumab
BioInvent International AB
Phase 1/2
35
Barcelona, Madrid, Seville
2023-12-04
Recruiting
PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
NCT06717594Gram Negative Infections, Antimicrobial Resistance (AMR)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
60
Seville
2023-12-01
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Sabadell, Santander, Majadahonda, Valencia, Barcelona, Madrid, Seville
2023-12-01
Recruiting
Octapharma
Phase 4
28
Madrid, Seville
2023-11-28
Recruiting
Amgen
Phase 3
750
Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona
2023-11-16
Active, closed
Nektar Therapeutics
Phase 2
396
Alicante, Córdoba, Granada, Seville, Zaragoza
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza
2023-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Seville, Sabadell, Terrassa, Barakaldo, Majadahonda, Pozuelo de Alarcón, Pamplona, Oviedo
2023-11-14
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza
2023-11-14
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2/3
1,074
Seville, Zamora
2023-11-14
Active, closed
Xentria, Inc.
Phase 1/2
32
Barcelona, Seville
2023-11-10
Active, closed
AstraZeneca
Phase 3
1,835
Girona, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Seville, Valencia
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
L'Hospitalet de Llobregat, Majadahonda, El Palmar, Madrid, Málaga, Seville, Valencia
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
100
Barcelona, Cartagena, Badalona, Cantabria, San Pedro Alcántara, Málaga, Seville
2023-11-06
Active, closed
Amgen
Phase 3
633
Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia
2023-11-02
Active, closed
Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication
NCT06051461Obesity, Metabolic Syndrome, Metabolic Disorder, Inflammation
University of Seville
Not applicable
40
Seville
2023-11-01
Active, closed
Ipsen
Observational
1,057
Badalona, Barcelona, Madrid, Seville, Vigo, Zaragoza
2023-11-01
Active, closed
IDEAYA Biosciences
Phase 2/3
420
L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville, Valencia
2023-10-31
Recruiting
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
170
Seville, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Oviedo, Valencia, Barcelona
2023-10-27
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
Madrid, Seville
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
402
Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Barcelona, Madrid, Salamanca, Seville, Terrassa
2023-10-23
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsAdagrasib·Cabozantinib
Kura Oncology, Inc.
Phase 1
300
Barcelona, Madrid, Seville
2023-10-18
Active, closed
Pharmacosmos A/S
Phase 4
302
Seville
2023-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Alcorcón, Alicante, Barcelona, Bilbao, Madrid, Palma de Mallorca, Santiago de Compostela, Seville
2023-10-12
Active, closed
Ipsen
Phase 3
759
Madrid, Málaga, Seville, Valencia
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia
2023-10-12
Active, closed
Stichting European Myeloma Network
Phase 3
759
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia
2023-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Torrevieja, Córdoba, Málaga, Seville, Calella, Barcelona, Centelles, L'Hospitalet de Llobregat
2023-10-09
Active, closed
Incyte Corporation
Phase 2
63
Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville
2023-10-09
By invitation
Biogen
Phase 3
306
Valladolid, Córdoba, Majadahonda, Barcelona, Seville
2023-10-03
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
94
Barcelona, Madrid, Seville
2023-09-28
Active, closed
NEOS Surgery
Not applicable
90
Barcelona, Pamplona, Madrid, Seville
2023-09-27
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Logroño, Málaga, Barcelona, Madrid, Seville
2023-09-26
Active, closed
AbbVie
Phase 2
130
Santander, Córdoba, Majadahonda, Pamplona, Barcelona, Madrid, Seville, Zaragoza
2023-09-21
Active, closed
PharmaMar
Phase 3
469
A Coruña, Barcelona, Madrid, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza
2023-09-21
Recruiting
Aesculap AG
Observational
2,998
Madrid, Santa Cruz de Tenerife, Seville
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Santiago de Compostela, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Seville, Valencia
2023-09-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra
2023-09-13
Active, closed
Bristol-Myers Squibb
Phase 3
774
Mérida, Santander, San Cristóbal de La Laguna, A Coruña, Santiago de Compostela, Seville
2023-09-11
Recruiting
Hoffmann-La Roche
Phase 3
230
A Coruña, Barcelona, Madrid, Málaga, Seville
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville
2023-09-07
By invitation
Development of a Wearable Device for Osteoporosis Prevention and Fracture Risk Reduction in Women
NCT06741956Osteoporosis in Post-menopausal Women, Prevention, Exercise, Physical Activity
University of Seville
Not applicable
120
Seville
2023-09-01
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Badalona, Barcelona, Cáceres, Madrid, Santander, Seville, Valencia
2023-08-31
Recruiting
Ipsen
Phase 3
276
Barcelona, Madrid, Majadahonda, Málaga, Pontevedra, Sabadell, Seville, Valencia
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville
2023-08-31
Active, closed
Pharming Technologies B.V.
Phase 3
16
Seville
2023-08-30
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Badalona, Barcelona, Córdoba, Madrid, Sabadell, Santiago de Compostela, Seville, Valencia
2023-08-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2023-08-18
Recruiting
Glaukos Corporation
Phase 2
84
Barcelona, Madrid, Seville, Zaragoza
2023-08-17
Active, closed
Emalex Biosciences Inc.
Phase 3
150
Madrid, Oviedo, Seville
2023-08-16
Active, closed
AstraZeneca
Phase 3
142
Barcelona, Madrid, Pamplona, Seville
2023-08-16
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
Barcelona, Madrid, Piqueras, Seville
2023-08-08
Active, closed
Hoffmann-La Roche
Phase 3
459
Lleida, Barcelona, Córdoba, Lugo, Madrid, Seville
2023-08-08
Active, closed
AbbVie
Phase 3
1,014
A Coruña, Vigo, Seville
2023-07-25
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Majadahonda, Málaga, Barcelona, Lleida, Madrid, Salamanca, Seville, Valladolid
2023-07-11
Recruiting
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
NCT05999877Chronic Lymphocytic Leukemia
AstraZeneca
Observational
315
Almería, Córdoba, Granada, Jaén, Marbella, Málaga, Seville, Zaragoza
2023-07-11
Active, closed
Merck Sharp & Dohme LLC
Phase 1
95
L'Hospitalet de Llobregat, Madrid, Barcelona, Seville
2023-07-06
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Manises, Barcelona, Girona, Lleida, Lugo, Madrid, Seville
2023-07-06
Active, closed
Tissium
Not applicable
78
Seville
2023-07-04
Recruiting
Global Research Initiative for Patients Screening on MASH
NCT05651724MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
Julius Clinical
Observational
10,000
Seville
2023-06-30
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Santiago de Compostela, Palma, Barcelona, Majadahonda, Oviedo, Madrid, Málaga, Seville
2023-06-30
Active, closed
Viatris Innovation GmbH
Phase 3
451
Alcobendas, Barcelona, Colmenar Viejo, Madrid, Santiago de Compostela, Seville, Valencia, Valladolid
2023-06-26
Active, closed
Alumis Inc
Phase 2
408
A Coruña, Alicante, Barcelona, Seville, Valencia
2023-06-26
Recruiting
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
NCT06896890NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer
Inhatarget Therapeutics
Phase 1/2
32
Barcelona, Madrid, Seville
2023-06-23
Recruiting
Population Health Research Institute
Not applicable
5,100
Madrid, Seville, Valencia, Valladolid
2023-06-22
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Badalona, Barcelona, Madrid, Seville, Valencia
2023-06-20
Recruiting
ModernaTX, Inc.
Observational
60
Esplugues de Llobregat, Santander, Barakaldo, Madrid, Seville, Valencia
2023-06-16
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
A Coruña, Barcelona, Pamplona, Seville
2023-06-07
By invitation
AbbVie
Phase 3
650
Barcelona, Madrid, Seville, Valencia
2023-06-05
Recruiting
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT05908409Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
DrugIDP-121
IDP Discovery Pharma S.L.
Phase 1/2
37
Santander, Salamanca, Barcelona, Madrid, Murcia, Seville, Valencia, Zaragoza
2023-06-05
Active, closed
Eli Lilly and Company
Phase 3
3,127
A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid
2023-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
Esplugues de Llobregat, Barcelona, A Coruña, Madrid, Seville
2023-05-31
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
225
Barcelona, Madrid, Málaga, Seville
2023-05-26
Active, closed
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugEribulin
MedSIR
Phase 2
14
Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona
2023-05-24
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
Alicante, Barcelona, Madrid, Seville, Valencia
2023-05-18
Recruiting
Pfizer
Phase 2
100
Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia
2023-05-17
Recruiting
Takeda
Phase 3
240
Sagunto, Barcelona, Madrid, Málaga, Seville
2023-05-16
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
DrugsIvonescimab·Pemetrexed·Carboplatin
Summit Therapeutics
Phase 3
420
A Coruña, Barcelona, Las Palmas, Lugo, Madrid, Majadahonda, Málaga, Seville
2023-05-04
Recruiting
AbbVie
Phase 3
450
Barcelona, Madrid, Seville, Valencia
2023-05-01
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Barcelona, Huelva, León, Salamanca, Seville
2023-04-25
Active, closed
Hoffmann-La Roche
Phase 2
199
Córdoba, Barcelona, Madrid, Seville, Valencia
2023-04-21
Active, closed
Klus Pharma Inc.
Phase 2
356
Majadahonda, Pozuelo de Alarcón, Barcelona, Málaga, Seville, Valencia
2023-04-19
Recruiting
Eli Lilly and Company
Phase 1/2
880
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Seville
2023-04-17
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia
2023-04-14
Recruiting
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2
24
San Sebastián, Seville, Madrid
2023-04-12
By invitation
Sanofi
Phase 2
70
Seville, Santander, Badalona, Madrid, Pamplona, Salamanca
2023-04-05
Active, closed
Alfasigma S.p.A.
Phase 3
495
Alicante, Barcelona, Bilbao, Córdoba, Madrid, Santander, Santiago de Compostela, Seville
2023-04-05
Active, closed
Bayer
Phase 3
985
Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville
2023-04-03
By invitation
Oral Health Promotion Program in Schools in Polígono Sur
NCT06797778Educational and Preventive Session for Dental Caries, Oral Diseases
University of Seville
Observational
396
Seville
2023-03-31
Active, closed
Bial R&D Investments, S.A.
Phase 2
237
Badalona, Barakaldo, Barcelona, Madrid, Seville
2023-03-31
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia
2023-03-30
Active, closed
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan
Enliven Therapeutics
Phase 1
198
Lleida, Seville, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
2023-03-20
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
1,166
Barcelona, Madrid, Málaga, Seville
2023-03-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
Santander, Barcelona, Seville
2023-03-16
Active, closed
Insmed Incorporated
Phase 2/3
91
Santander, Seville
2023-03-07
Active, closed
BeiGene
Phase 2
400
Barcelona, Madrid, Seville
2023-03-07
Active, closed
AstraZeneca
Phase 2
188
Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
2023-03-06
Recruiting
Takeda
Phase 3
160
Barcelona, Málaga, Santander, Seville
2023-03-06
Recruiting
High Definition Medicine for Solid Tumors Oncology
NCT06590506Metastatic Solid Tumor, Advanced Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III
Observational
300
A Coruña, Fuenlabrada, Palma de Mallorca, Pamplona, Seville, Barcelona, Cáceres, Madrid
2023-03-02
Active, closed
Pfizer
Phase 1/2
20
Madrid, Seville
2023-03-01
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Barakaldo, Barcelona, Madrid, Seville, Valencia
2023-02-27
Active, closed
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
W.L.Gore & Associates
Observational
320
Seville
2023-02-24
Active, closed
Pfizer
Phase 1/2
37
Barcelona, Madrid, Pamplona, Seville
2023-02-23
Recruiting
Fore Biotherapeutics
Phase 2
254
Santiago de Compostela, Barcelona, Madrid, Seville, Valencia
2023-02-21
Active, closed
Gilead Sciences
Phase 2
400
Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia
2023-02-21
Active, closed
Kite, A Gilead Company
Phase 3
300
Barcelona, Madrid, Salamanca, Santander, Seville, Valencia
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Barcelona, Madrid, Murcia, Salamanca, Seville
2023-02-03
Active, closed
Hoffmann-La Roche
Phase 2
301
Barakaldo, Badajoz, Barcelona, Burgos, Madrid, Seville, Valencia
2023-02-03
Active, closed
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Observational
88
Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia
2023-01-23
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
Esplugues de Llobregat, Sabadell, Barcelona, Seville
2023-01-23
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Badalona, Santander, Barcelona, Oviedo, Granada, Lugo, Madrid, Seville
2023-01-16
Active, closed
University of Seville
Observational
150
Seville
2023-01-15
Active, closed
Bristol-Myers Squibb
Phase 3
513
Mérida, Barcelona, Bilbao, Santander, Cordoba, Seville, Valencia, Valladolid
2023-01-12
Active, closed
Daiichi Sankyo
Phase 3
1,170
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza
2023-01-11
Active, closed
Zenas BioPharma (USA), LLC
Phase 3
194
Madrid, Barcelona, Seville
2023-01-09
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo
2023-01-02
Recruiting
GBG Forschungs GmbH
Phase 2
170
Barcelona, Granada, Lleida, Madrid, Murcia, Palma de Mallorca, Santander, Seville
2023-01-02
Recruiting
Technische Universität Dresden
Observational
318,542
Sabadell, Seville
2023-01-01
By invitation
BioMarin Pharmaceutical
Observational
172
Seville, A Coruña
2023-01-01
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Palma de Mallorca, Ponferrada, Torrejón de Ardoz, Benalmádena Costa, Barcelona, Seville, Valencia
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Las Palmas de Gran Canaria, Lugo, Madrid, Santander, Seville, Valencia, Zaragoza
2022-12-29
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia
2022-12-23
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Barcelona, Madrid, Seville
2022-12-21
Active, closed
PETHEMA Foundation
Phase 2
140
Madrid, Palma de Mallorca, Pamplona, Salamanca, San Cristóbal de La Laguna, Santander, Seville, Valencia
2022-12-15
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Barcelona, Madrid, Seville, Valencia
2022-12-15
Active, closed
Amgen
Phase 3
7,297
Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat
2022-12-14
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
A Coruña, Alicante, Barcelona, Madrid, Seville, Valencia
2022-12-13
Active, closed
Agenus Inc.
Phase 2
150
Barcelona, Donostia / San Sebastian, Madrid, Seville, Valencia
2022-12-12
Active, closed
AbbVie
Phase 1
288
Barcelona, Madrid, Seville, Valencia
2022-12-05
Recruiting
The Impact of Radiotherapy on Oligometastatic Cancer
NCT05933876Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer
Institut Investigacio Sanitaria Pere Virgili
Observational
2,000
Albacete, Barcelona, Granada, Lleida, Madrid, Seville, Reus, Valencia
2022-12-01
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
297
Barakaldo, Barcelona, Jerez de la Frontera, Madrid, Murcia, Sabadell, Seville, Valencia
2022-11-23
Active, closed
Mirati Therapeutics Inc.
Phase 2
90
A Coruña, Madrid, Majadahonda, Palma de Mallorca, Seville, Zaragoza
2022-11-22
Active, closed
Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence
NCT05424484Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
Medtronic - MITG
Not applicable
123
Igualada, Barcelona, Madrid, Seville
2022-11-22
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Badalona (Barcelona), Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2022-11-21
Recruiting
Phrenic Nerve Infiltration in Neck Pain
NCT05605639Chronic Neck Pain
DrugBupivacaine
University of Seville
Phase 4
60
Dos Hermanas, Seville
2022-11-17
Recruiting
Janssen Research & Development, LLC
Phase 2
520
A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia
2022-11-11
Active, closed
AstraZeneca
Phase 3
368
Barcelona, Madrid, Pamplona, Seville, Tomelloso
2022-11-10
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Barcelona, Madrid, Murcia, Sabadell, Seville, Valencia
2022-11-08
Recruiting
Bayer
Phase 3
100
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville
2022-11-08
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Córdoba, Madrid, Salamanca, Seville
2022-11-07
Recruiting
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
NCT05607420B-cell Non-Hodgkin Lymphoma (B-NHL)
DrugAlemtuzumab
Cellectis S.A.
Phase 1/2
80
Pamplona, Seville
2022-11-01
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Pamplona, Barcelona, Castilleja de la Cuesta, León, Madrid, Seville
2022-11-01
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Badalona, Barcelona, Majadahonda, Seville
2022-10-28
Active, closed
Almirall, S.A.
Phase 4
447
Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza
2022-10-24
Active, closed
AbbVie
Phase 1
283
L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Seville
2022-10-20
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia
2022-10-14
Recruiting
POS-cUTI: Study on Complicated Urinary Tract Infections
NCT05458700Urinary Tract Infections
European Clinical Research Alliance for Infectious Diseases (ECRAID)
Observational
16,000
Seville
2022-10-10
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
2022-10-04
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Barcelona, Ferrol, Girona, Madrid, Majadahonda, Seville, Vigo, Zaragoza
2022-09-27
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Alicante, Barcelona, Bilbao, Donostia / San Sebastian, Madrid, Seville
2022-09-23
Active, closed
Kite, A Gilead Company
Phase 3
231
Barcelona, Madrid, Salamanca, Seville, Valencia
2022-09-22
Active, closed
Eli Lilly and Company
Phase 2
46
Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia
2022-09-20
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Zaragoza
2022-09-19
Active, closed
XIENCE Skypoint Large Vessel Post Approval Study
NCT05423379Coronary Artery Disease
Abbott Medical Devices
Observational
102
Madrid, Santander, Seville
2022-09-14
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Badalona, Seville, Villajoyosa, Zaragoza
2022-09-13
Recruiting
AstraZeneca
Phase 2
454
Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Barcelona, Seville
2022-09-05
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Majadahonda, Barcelona, Madrid, Seville
2022-08-26
Active, closed
Biogen
Phase 2
416
Pamplona, Getxo, Barcelona, Córdoba, Lleida, Seville, Valencia
2022-08-24
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
209
Santiago de Compostela, Madrid, Seville
2022-08-23
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Barcelona, Madrid, Salamanca, Seville, Valladolid, Zamora, Zaragoza
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Badalona, Bilbao, Las Palmas de Gran Canaria, Pamplona, Pontevedra, Vigo, Seville, Burjassot
2022-08-22
Recruiting
Fundacion Clinic per a la Recerca Biomédica
Phase 4
360
Alicante, Seville, Palma de Mallorca, Barcelona, Sabadell, Terrassa, Barakaldo, Santander
2022-08-17
Active, closed
Gilead Sciences
Phase 2/3
689
Barcelona, Madrid, Seville
2022-08-16
Active, closed
AbbVie
Observational
785
L'Hospitalet de Llobregat, Sabadell, Las Palmas de Gran Canaria, Gijón, San Cristóbal de La Laguna, Seville, Galdakao, Almería
2022-08-15
Recruiting
Novartis Pharmaceuticals
Phase 2
240
Port de Sagunt, Barcelona, Ciudad Real, Madrid, Seville
2022-08-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville
2022-08-04
Active, closed
BlueRock Therapeutics
Observational
194
Santurtzi, Barcelona, Pontevedra, Seville, Valencia
2022-07-29
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville
2022-07-22
Active, closed
Gilead Sciences
Phase 3
623
A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia
2022-07-20
Active, closed
Incyte Corporation
Phase 1/2
53
Palma de Mallorca, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Seville, Valencia
2022-07-19
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
Seville, L'Hospitalet Del Llobregat, Madrid
2022-07-14
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
154
Barcelona, Madrid, Seville, Valencia
2022-07-13
Active, closed
Pfizer
Phase 2
108
Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza
2022-07-11
Active, closed
Daiichi Sankyo
Phase 3
586
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville
2022-07-08
Active, closed
AstraZeneca
Phase 3
53
Badalona, Santiago de Compostela, Seville
2022-07-01
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
A Coruña, Córdoba, Málaga, Santiago de Compostela, Seville, Valencia
2022-06-30
Active, closed
Cousin Biotech
Not applicable
196
Seville
2022-06-30
Recruiting
Orphalan
Observational
500
Las Palmas de Gran Canaria, Barcelona, Seville, Valencia
2022-06-29
Recruiting
AstraZeneca
Phase 1/2
695
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Seville
2022-06-24
Recruiting
BioNTech SE
Phase 1
320
Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia
2022-06-17
Active, closed
Genmab
Phase 2
264
Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2022-06-14
By invitation
Biogen
Phase 3
864
Castellon, Santander, Seville, Barcelona
2022-06-10
Recruiting
Astellas Pharma Inc
Phase 1
681
Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia
2022-06-08
Recruiting
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05211570Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
DrugVenetoclax
AB Science
Phase 1/2
78
Alicante, Cáceres, Madrid, Pamplona, Seville
2022-06-01
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Almería, Barcelona, Córdoba, Madrid, Majadahonda, Seville
2022-05-30
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Barcelona, Madrid, Málaga, Santiago de Compostela, Seville
2022-05-23
Active, closed
Hoffmann-La Roche
Phase 3
188
Esplugues de Llobregas, Barcelona, Madrid, Seville
2022-05-19
Recruiting
Electra Therapeutics Inc.
Phase 2/3
156
Madrid, Pamplona, Seville, Valencia
2022-05-19
Active, closed
IO Biotech
Phase 3
407
Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia
2022-05-17
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Badajoz, Badalona, Barcelona, Córdoba, Madrid, Seville, Valdecilla, Valencia
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville
2022-05-16
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Sabadell, Barcelona, Madrid, Seville
2022-05-03
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Barcelona, El Palmar, Madrid, Santiago de Compostela, Seville, Zaragoza
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
925
Hospitalet, Madrid, Valencia, Badajoz, Seville
2022-04-14
Active, closed
Verastem, Inc.
Phase 1/2
153
A Coruña, Madrid, Málaga, Seville
2022-04-12
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Barcelona, Córdoba, Ellenboro, Madrid, Seville
2022-04-05
Recruiting
Luis María Béjar Prado
Not applicable
322
Seville
2022-04-04
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Barcelona, Córdoba, Madrid, Seville
2022-03-30
Active, closed
Bayer
Phase 3
219
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Barcelona, Córdoba, Lugo, Madrid, Málaga, Sabadell, Seville
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Madrid, Málaga, Barcelona, Seville
2022-03-24
Active, closed
Abbott Medical Devices
Not applicable
100
Badalona, Madrid, Seville
2022-03-24
Active, closed
Pfizer
Phase 1/2
235
Barcelona, Madrid, Seville
2022-03-14
Active, closed
Daiichi Sankyo
Phase 2
187
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2022-03-09
Active, closed
Daiichi Sankyo
Phase 3
740
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2022-03-04
Recruiting
Pfizer
Phase 3
640
Sabadell, Valladolid, Vigo, Valencia, Madrid, Seville
2022-02-28
Active, closed
Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)
NCT06030544Diabetic Patients, Type II Diabetes Mellitus
Spanish National Research Council
Phase 2
100
Seville
2022-02-25
Recruiting
Takeda
Phase 3
120
Esplugues de Llobregat, Sagunto, Madrid, Málaga, Seville
2022-02-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville
2022-02-03
By invitation
UCB Biopharma SRL
Phase 3
300
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid
2022-02-03
Active, closed
UCB Biopharma SRL
Phase 3
113
Barcelona, Madrid, Málaga, Murcia, Seville
2022-02-02
Active, closed
Denali Therapeutics Inc.
Phase 1/2
85
Barcelona, Donostia / San Sebastian, Seville
2022-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Gijón, Huelva, Madrid, Seville, Vigo, Villajoyosa
2022-01-19
Recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Not applicable
608
Alcalá de Henares, Barcelona, Granada, Madrid, Salamanca, Seville, Valladolid
2022-01-18
Active, closed
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville
2022-01-11
Active, closed
Noema Pharma AG
Phase 2/3
166
Madrid, Seville, Valencia
2022-01-11
Active, closed
SK Life Science, Inc.
Phase 3
140
Barcelona, Madrid, Seville
2022-01-10
Active, closed
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
NCT04685590Alzheimer Disease, Early Onset, Mild Cognitive Impairment
DrugsDasatinib·Ribociclib
Washington University School of Medicine
Phase 2
48
Barcelona, Seville
2021-12-22
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
194
Barcelona, Madrid, Murcia, Seville
2021-12-20
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Cadiz, Seville, Barcelona, Sant Joan Despí, Salt, Alcorcón, Getafe, Majadahonda
2021-12-16
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia
2021-12-14
Recruiting
UCB Biopharma SRL
Phase 3
350
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid
2021-12-07
Active, closed
Sanofi
Phase 2
22
Barakaldo, Barcelona, Madrid, Seville
2021-12-07
Recruiting
H. Lundbeck A/S
Phase 3
600
Vigo, Barcelona, Madrid, Seville, Valencia
2021-12-01
Active, closed
Agios Pharmaceuticals, Inc.
Phase 3
258
Barcelona, Madrid, Murcia, Seville
2021-11-30
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Ferrol, Santiago Compostela, Seville, Mallorca, Palma, el Prat de Llobregat, L'Hospitalet de Llobregat, Sabadell
2021-11-23
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
60
Barcelona, Madrid, Seville
2021-11-18
Active, closed
Hoffmann-La Roche
Phase 3
660
A Coruña, Barcelona, Madrid, Málaga, Seville
2021-11-18
Active, closed
Janssen Research & Development, LLC
Phase 3
776
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville
2021-11-17
Active, closed
Clinical Trial With Artiflex Presbyopic (Artiplus)
NCT04632784Presbyopia, Ametropia, Refractive Errors, Myopia
Ophtec BV
Not applicable
49
Bilbao, Barcelona, Madrid, Seville
2021-11-12
Active, closed
Amgen
Phase 3
303
Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia
2021-11-02
Active, closed
AstraZeneca
Phase 3
148
A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Guipuzcoa, Madrid, Murcia, Seville, Valencia
2021-10-27
Active, closed
AstraZeneca
Phase 3
927
Barcelona, Madrid, Seville, Vigo
2021-10-25
Active, closed
Hoffmann-La Roche
Phase 3
83
A Coruña, Barcelona, Seville
2021-10-22
Active, closed
AstraZeneca
Phase 3
732
A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2021-10-18
Active, closed
AbbVie
Phase 1
520
Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville
2021-10-13
Active, closed
Beeline Medicines Corporation
Phase 2
248
Santander, A Coruña, Barcelona, Madrid, Seville
2021-10-11
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Barakaldo, Seville
2021-10-05
Active, closed
Eli Lilly and Company
Phase 3
874
Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville
2021-10-04
Active, closed
Pfizer
Phase 3
77
Barcelona, L'Hospitalet de Llobregat, Madrid, Seville
2021-09-29
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
DrugINBRX-109
Inhibrx Biosciences, Inc
Phase 2
206
Barcelona, Madrid, Santiago de Compostela, Seville, Valencia
2021-09-23
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Madrid, Oviedo, Barcelona, Seville
2021-09-23
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Barcelona, Madrid, Seville, Zaragoza
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Barcelona, Madrid, Majadahonda, Marbella, Oviedo, Pozuelo de Alarcón, Seville, Toledo
2021-09-20
Active, closed
Alligator Bioscience AB
Phase 1/2
94
Barcelona, Madrid, Seville, Zaragoza
2021-09-17
Active, closed
Hoffmann-La Roche
Phase 1/2
42
Madrid, Seville, Valencia
2021-09-14
Recruiting
Amgen
Phase 3
60
Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid
2021-09-09
Active, closed
Nuvation Bio Inc.
Phase 2
217
Barcelona, Madrid, Málaga, Seville, Valencia
2021-09-01
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville
2021-08-19
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
DrugSparsentan
Travere Therapeutics, Inc.
Phase 2
67
Barcelona, Madrid, Seville
2021-08-12
Active, closed
HUYABIO International, LLC.
Phase 3
450
Barcelona, Madrid, Málaga, Seville, Zaragoza
2021-08-12
Active, closed
AstraZeneca
Phase 3
712
Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville
2021-08-05
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Barcelona, Madrid, Málaga, Seville, Valencia, Las Palmas de Gran Canaria
2021-08-04
Active, closed
Assistance Publique - Hôpitaux de Paris
Phase 3
800
Badalona, Barcelona, Cartagena, Galdakao, Madrid, Seville, Valencia
2021-08-04
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Barcelona, Port de Sagunt, Madrid, Málaga, Seville
2021-07-28
Recruiting
Bristol-Myers Squibb
Phase 3
102
Barcelona, Rivas-Vaciamadrid, Seville
2021-07-21
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Alicante, Barcelona, Bilbao, Seville, Valencia
2021-07-15
Active, closed
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
DrugTabelecleucel
Pierre Fabre Medicament
Phase 2
190
Barcelona, Madrid, Seville
2021-07-14
Active, closed
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
NCT04788888Symptomatic Severe Aortic Stenosis
Abbott Medical Devices
Not applicable
434
Madrid, Alicante, Barcelona, Seville
2021-07-13
Active, closed
VectivBio AG
Phase 3
158
Madrid, Seville
2021-07-13
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
European Foundation for Study of Chronic Liver Failure
Observational
3,000
Barcelona, Madrid, Santander, Seville, Valencia
2021-07-08
Active, closed
Britannia Pharmaceuticals Ltd.
Observational
312
Barcelona, Madrid, Seville
2021-07-06
Recruiting
H. Lundbeck A/S
Phase 3
285
Barcelona, Seville, Sevilla, Madrid
2021-06-30
Active, closed
Hoffmann-La Roche
Phase 3
142
L'Hospitalet de Llobregat, Barcelona, Madrid, Seville
2021-06-25
Active, closed
Neurocrine Biosciences
Phase 3
103
Barcelona, Seville
2021-06-25
Recruiting
Philips Clinical & Medical Affairs Global
Not applicable
594
Madrid, Barcelona, Girona, Seville
2021-06-23
Active, closed
AstraZeneca
Phase 3
506
Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville
2021-06-22
Recruiting
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
102
Barcelona, Burgos, Seville
2021-06-18
Active, closed
AstraZeneca
Phase 3
367
Barcelona, Madrid, Santiago de Compostela, Seville, Valencia
2021-06-08
Active, closed
Daiichi Sankyo
Phase 2
155
Barcelona, Madrid, Seville
2021-06-03
Active, closed
Biogen
Phase 3
548
Santander, Valladolid, Barcelona, Granada, Seville, Valencia
2021-05-25
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Barcelona, Salamanca, Seville, Valencia
2021-05-24
Active, closed
Bristol-Myers Squibb
Phase 3
681
Barcelona, Madrid, Sabadell, Santander, Seville
2021-05-21
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
2021-05-19
Active, closed
CNS Pharmaceuticals, Inc.
Phase 2
252
Badalona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2021-05-18
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
170
A Coruña, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Seville
2021-05-07
By invitation
Cytokinetics
Phase 2/3
900
A Coruña, Barcelona, Madrid, Málaga, Palma, Pontevedra, Salamanca, Seville
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 3
761
Sabadell, Santander, Córdoba, Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2021-05-03
Recruiting
Ipsen
Phase 1/2
240
A Coruña, Barcelona, Huelva, Madrid, Santiago de Compostela, Seville, Vigo
2021-04-29
Active, closed
AstraZeneca
Phase 3
1,157
Alicante, Barcelona, Madrid, Majadahonda, Seville
2021-04-26
Recruiting
Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics
NCT05761080Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess
DrugMaximum
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase 4
772
Barcelona, Córdoba, Lleida, Madrid, Seville, Badalona, Esplugues de Llobregat, Girona
2021-04-22
Recruiting
ModernaTX, Inc.
Phase 1/2
77
Esplugues de Llobregat, Barakaldo, Madrid, Seville
2021-04-15
Active, closed
Eli Lilly and Company
Phase 3
101
Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia
2021-04-13
Recruiting
Gilead Sciences
Phase 1
30
Barcelona, Seville
2021-04-06
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Pontevedra, Barcelona, Majadahonda, Santander, Seville, Valencia, Valladolid
2021-04-01
Recruiting
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Observational
540
Seville
2021-04-01
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Castellon, Barcelona, Córdoba, Girona, Madrid, Málaga, Seville, Valencia
2021-03-18
Active, closed
Hoffmann-La Roche
Phase 3
746
L'Hospitalet de Llobregat, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Madrid, Málaga, Seville
2021-03-17
Recruiting
UCB Biopharma SRL
Phase 3
70
Seville
2021-03-11
Recruiting
AstraZeneca
Phase 1
304
Badalona, Madrid, Seville, Valencia
2021-03-09
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Seville, Barcelona, Donostia / San Sebastian, Granada, Madrid, Majadahonda, Salamanca, Santander
2021-03-04
Active, closed
German CLL Study Group
Phase 3
897
Badalona, Barcelona, Madrid, Málaga, Oviedo, Salamanca, Santander, Seville
2021-03-01
Active, closed
Celgene
Phase 3
313
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville
2021-02-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
A Coruña, Madrid, Barcelona, Seville
2021-02-25
Active, closed
AstraZeneca
Phase 2
31
Seville, Valencia
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Barcelona, Madrid, Seville, Valencia
2021-02-23
Active, closed
Sellas Life Sciences Group
Phase 3
127
Cáceres, Córdoba, Madrid, Oviedo, Pamplona, Salamanca, Seville, Valencia
2021-02-08
Active, closed
Hoffmann-La Roche
Phase 3
55
Esplugues de Llobregat, Madrid, Seville
2021-02-04
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Seville, Badalona, Majadahonda, Barcelona, Madrid, Málaga, Zaragoza
2021-02-02
Active, closed
AstraZeneca
Phase 1
155
A Coruña, Badalona, Barcelona, Madrid, Seville
2021-02-02
Recruiting
Epygon
Not applicable
40
Badalona, Barcelona, Madrid, Murcia, Seville
2021-02-01
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Seville
2021-01-29
Active, closed
AstraZeneca
Phase 3
1,371
Barcelona, Jaén, Lleida, Madrid, Málaga, Pamplona, Santander, Seville
2021-01-28
Recruiting
Pfizer
Phase 3
2,100
Santander, Barcelona, Madrid, Seville, Valladolid
2021-01-15
Active, closed
Amgen
Phase 1/2
181
Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona
2021-01-04
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Barcelona, Madrid, Pamplona, Seville
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Barcelona, L'Hospitalet de Llobregat, Madrid, Seville
2020-12-28
Active, closed
Daiichi Sankyo
Phase 3
605
Barcelona, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2020-12-21
Active, closed
Pfizer
Phase 3
841
Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Barcelona, Madrid, Seville, Valencia, Zaragoza
2020-12-21
Active, closed
Neurocrine Biosciences
Phase 3
182
Madrid, Seville
2020-12-16
Recruiting
FS222 First in Human Study in Patients With Advanced Malignancies
NCT04740424Advanced Cancer, Metastatic Cancer
invoX Pharma Limited
Phase 1
260
Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville, Valencia
2020-12-14
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Barcelona, Madrid, Sagunto, Seville, Valencia
2020-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Málaga, Seville
2020-12-08
Active, closed
Instituto de Investigación Hospital Universitario La Paz
Phase 1/2
18
Santiago de Compostela, Oviedo, Barcelona, Madrid, Málaga, Murcia, Seville, Valencia
2020-11-30
Active, closed
Eli Lilly and Company
Phase 3
312
Barcelona, Seville, Valencia, Valladolid
2020-11-25
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Barcelona, Coaña, Madrid, Seville, Valencia
2020-11-25
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
68
L'Hospitalet de Llobregat, Barcelona, Madrid, Palma de Mallorca, Pamplona, Seville
2020-11-17
Active, closed
AstraZeneca
Phase 3
957
Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia
2020-11-17
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Cadiz, Ferrol, Jerez de la Frontera, Madrid, Málaga, Pamplona, Seville, Valencia
2020-11-12
Active, closed
AstraZeneca
Phase 1/2
702
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2020-11-12
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Barcelona, Gijón, Granada, Madrid, Majadahonda, Pamplona, Salamanca, Seville
2020-11-03
Active, closed
Hoffmann-La Roche
Phase 3
992
L'Hospitalet de Llobregat, Donostia / San Sebastian, Pozuelo de Alarcón, A Coruña, Barcelona, Madrid, Seville, Valencia
2020-10-09
Active, closed
Ipsen
Phase 3
161
Barcelona, Madrid, Pontevedra, San Sebastián, Santander, Seville
2020-09-24
Recruiting
University of Birmingham
Phase 1/2
1,672
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Zaragoza
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Barcelona, Cáceres, Madrid, Santander, Seville, Valencia
2020-09-16
Active, closed
AbbVie
Phase 3
531
Badalona, Córdoba, Pozuelo de Alarcón, Barcelona, Madrid, Salamanca, Seville, Valencia
2020-09-10
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Argentona, Santiago de Compostela, A Gudiña, Las Cabezas de San Juan, Barcelona, Jaén, Madrid, Seville
2020-09-03
Active, closed
Karyopharm Therapeutics Inc
Phase 2/3
501
Badalona, Barcelona, Madrid, Seville
2020-09-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Barcelona, Gijón, Majadahonda, Pamplona, Seville
2020-08-25
Recruiting
Takeda
Phase 2
160
Barcelona, Salamanca, Seville, Valencia
2020-08-19
Active, closed
MedImmune LLC
Phase 1
67
Barcelona, Córdoba, Madrid, Sabadell, Seville, Valencia
2020-08-05
Active, closed
Genentech, Inc.
Phase 1
498
Barcelona, Madrid, Málaga, Seville, Valencia
2020-07-29
Active, closed
AstraZeneca
Phase 3
866
A Coruña, Barcelona, Córdoba, El Palmar, Madrid, San Sebastián, Seville, Valencia
2020-07-24
Active, closed
Celgene
Phase 2
276
Madrid, Salamanca, Seville
2020-07-14
Active, closed
GlaxoSmithKline
Phase 3
242
Barcelona, Madrid, Seville, Valencia
2020-07-14
Active, closed
AstraZeneca
Phase 3
1,012
Badalona (Barcelona), Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Seville
2020-07-13
Recruiting
Mats Heyman
Phase 3
6,430
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Palma de Mallorca, Seville, Valencia, Zaragoza
2020-07-13
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Cadiz, Cartagena, Granada, Ourense, Seville, Valencia
2020-07-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Majadahonda, Pozuelo de Alarcón, Málaga, Barcelona, Seville, Valencia
2020-07-06
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
A Coruña, Córdoba, Madrid, Seville
2020-07-01
Recruiting
BioInvent International AB
Phase 1/2
197
Barcelona, Majadahonda, Málaga, Pamplona, Seville
2020-06-29
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville
2020-06-12
Active, closed
Epizyme, Inc.
Phase 3
599
Barcelona, Marbella, El Palmar, Madrid, Pamplona, Salamanca, Seville
2020-06-11
Active, closed
AstraZeneca
Phase 2
452
Barcelona, Madrid, Santander, Seville
2020-06-03
Active, closed
Autolus Limited
Phase 1/2
153
Barcelona, Seville, Valencia
2020-06-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
L'Hospitalet de Llobregat, Valencia, Seville
2020-05-19
Recruiting
Spanish Registry of Esophagogastric Cancer
NCT04958720Esophageal Cancer, Gastric Cancer
Fundación Sociedad Española de Oncologia Médica
Observational
10,000
Alicante, Elche, Elda, Córdoba, Málaga, Seville, Palma de Mallorca, Barcelona
2020-04-27
Active, closed
AstraZeneca
Phase 2
240
Barcelona, Madrid, Seville, Zaragoza
2020-04-22
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Seville, Valencia
2020-03-12
Active, closed
Amgen
Phase 3
145
Granada, Seville, Salamanca, Barcelona, Ourense, Fuenlabrada, Castellon, Madrid
2020-02-26
Active, closed
Eli Lilly and Company
Phase 3
58
Esplugues de Llobregat, Madrid, Seville, Valencia
2020-02-12
Active, closed
Daiichi Sankyo
Phase 1
115
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Seville, Zaragoza
2020-02-10
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Badalona, Pamplona, San Cristóbal de La Laguna, Barcelona, Jaén, Madrid, Seville, Valencia
2020-01-29
Recruiting
Eli Lilly and Company
Phase 2
105
Barcelona, Esplugues de Llobregat, Madrid, San Cristóbal de La Laguna, Seville, Valencia
2020-01-22
Active, closed
Actelion
Phase 3
138
A Coruña, Barcelona, Esplugues de Llobregat, Madrid, Seville
2020-01-16
By invitation
Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis
NCT05492565HIV Infection Primary, Hepatitis, Viral, Human, Sexually Transmitted Infections, Excluding HIV and Hepatitis
DrugsTenofovir Disoproxil Fumarate·Emtricitabine
Hospitales Universitarios Virgen del Rocío
Observational
500
Seville
2020-01-01
Active, closed
USWM CT, LLC
Phase 2
103
Barcelona, Hospitalet de Llobregat, Barcelona, Madrid, Seville
2019-12-31
Recruiting
Amgen
Phase 3
24
Seville, Barcelona
2019-12-20
Active, closed
SOLTI Breast Cancer Research Group
Not applicable
180
Badalona, Barcelona, Jerez de la Frontera, Santa Cruz de Tenerife, Lleida, Madrid, Seville, Valencia
2019-12-13
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
DrugLAM561
Laminar Pharmaceuticals
Phase 2/3
144
Córdoba, Seville, Barcelona, Madrid, Valencia, Sabadell
2019-12-01
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Seville, Badalona, Madrid
2019-11-26
Active, closed
Gilead Sciences
Phase 2/3
72
Badalona, Barcelona, Madrid, Seville
2019-11-21
Active, closed
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
Universitätsklinikum Hamburg-Eppendorf
Phase 2
167
Badalona, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-11-14
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Madrid, Málaga, Oviedo, Seville, Valencia
2019-11-13
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
L'Hospitalet de Llobregat, Seville, Valencia
2019-11-05
Recruiting
GlaxoSmithKline
Phase 1/2
184
BaracaldoVizcaya, Espluges de Llobregat, HebrOn, Madrid, Seville
2019-10-25
Active, closed
Novo Nordisk A/S
Phase 3
134
Barcelona, Madrid, Málaga, Oviedo, Seville
2019-10-21
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Pamplona, Barcelona, Madrid, Seville
2019-10-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Palma de Mallorca, Barcelona, San Cristóbal de La Laguna, Córdoba, Madrid, Sant Joan Despí, Seville, Valencia
2019-10-02
Active, closed
University of Zurich
Observational
540
Barcelona, Seville, Valencia
2019-10-01
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Seville
2019-10-01
Active, closed
NeuroDerm Ltd.
Phase 3
381
Oviedo, Alicante, Barcelona, Burgos, Madrid, Seville, Valencia
2019-09-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Badalona, Barcelona, Girona, Madrid, Santander, Seville
2019-09-26
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Badalona, El Palmar, A Coruña, Barcelona, Córdoba, Seville, Valencia
2019-09-20
Active, closed
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
DrugsZiftomenib·Itraconazole·Midazolam
Kura Oncology, Inc.
Phase 1/2
263
Barcelona, Madrid, Oviedo, Seville, Valencia
2019-09-12
Active, closed
LITMUS Imaging Study
NCT05479721NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
University of Oxford
Observational
450
Barcelona, Seville, Valladolid
2019-09-04
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Barcelona, Madrid, Seville
2019-09-04
Recruiting
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
NCT04832607AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
Tobias Feuchtinger
Phase 3
149
Barcelona, Madrid, Seville, Valencia
2019-08-27
Active, closed
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
USWM CT, LLC
Phase 1
120
Madrid, Pío, Ibanez, Barcelona, Seville
2019-08-20
Active, closed
BeOne Medicines
Phase 3
510
Barcelona, Girona, Madrid, Málaga, Seville
2019-08-20
Active, closed
USWM CT, LLC
Phase 2
52
Barcelona, Madrid, Seville
2019-08-13
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Barakaldo, Barcelona, Madrid, Oviedo, Salamanca, Seville, Valencia
2019-08-12
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Pozuelo de Alarcón, El Palmar, Vigo, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-08-12
Active, closed
Bristol-Myers Squibb
Phase 3
839
Badalona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia
2019-08-05
Recruiting
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
NCT03711110Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Not applicable
514
Santiago de Compostela, Galdakao, Barcelona, Córdoba, Madrid, Málaga, Salamanca, Seville
2019-08-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Badalona, Barcelona, Cáceres, Girona, Pozuelo de Alarcón, Valencia, Madrid, Seville
2019-07-24
Active, closed
Amgen
Phase 3
457
Seville, Barcelona, Pamplona, Valencia
2019-07-19
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Barcelona, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
2019-07-09
Active, closed
Grupo Español de Investigación en Cáncer de Ovario
Phase 2
134
Elche, Donostia / San Sebastian, Girona, Madrid, Vigo, Seville, Valencia, Barcelona
2019-06-28
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
AstraZeneca
Phase 2
247
A Coruña, Barcelona, Madrid, Seville
2019-06-25
Active, closed
AstraZeneca
Phase 3
923
Badalona, Barcelona, Hospitalet deLlobregat, Jaén, Madrid, Málaga, Seville, Valencia
2019-06-25
Active, closed
Bristol-Myers Squibb
Phase 3
437
Barcelona, Córdoba, Madrid, Pamplona, Sabadell, Santander, Santiago Compostela, Seville
2019-06-21
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
366
Barcelona, Lleida, Madrid, Reus, Seville, Valencia
2019-06-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Barcelona, Alcorcón, Torrejón de Ardoz, Badalona, Madrid, Majadahonda, Salamanca, Seville
2019-06-04
Active, closed
Eisai Inc.
Phase 2
100
Madrid, Pamplona, Santiago de Compostela, Seville
2019-05-31
Recruiting
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Observational
1,750
Santiago de Compostela, Córdoba, Granada, Huelva, Málaga, Seville, Huesca, Zaragoza
2019-05-21
Active, closed
Novo Nordisk A/S
Phase 3
1,500
A Coruña, Barcelona, L'Hospitalet de Llobregat, Pamplona, Seville, Valencia
2019-05-08
Recruiting
Eli Lilly and Company
Phase 3
190
Esplugues de Llobregat, Madrid, Seville, Valencia
2019-04-05
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Majadahonda, Almería, Barcelona, Madrid, Pontevedra, Santander, Seville, Valencia
2019-03-28
Active, closed
Eisai Inc.
Phase 3
1,906
Sant Cugat del Vallès, Getxo, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Salamanca, Seville
2019-03-27
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Alicante, Badalona, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santander, Seville
2019-03-21
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
Sabadell, Santiago de Compostela, Barcelona, Madrid, Seville
2019-03-20
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609Parkinson Disease, Essential Tremor, Dystonia
Boston Scientific Corporation
Observational
5,000
Seville
2019-03-12
Active, closed
AstraZeneca
Phase 3
724
Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, San Sebastián, Santiago de Compostela, Seville
2019-03-06
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo
2019-02-08
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Seville, Badalona, Pamplona, Barcelona, Granada, Madrid, Málaga, Valencia
2019-01-30
Recruiting
RECORDATI GROUP
Observational
95
Barcelona, Bilbao, Madrid, Murcia, Palma de Mallorca, Seville, Zaragoza
2019-01-15
Active, closed
AstraZeneca
Phase 1
175
Barcelona, Madrid, Seville
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Barcelona, Madrid, Seville
2018-12-17
Active, closed
Travere Therapeutics, Inc.
Phase 3
406
Palma de Mallorca, Sagunto, Barcelona, Madrid, Seville, Valencia, Zaragoza
2018-12-11
Active, closed
AstraZeneca
Phase 3
1,063
Badalona, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Barcelona, Girona, Madrid, Málaga, Seville
2018-10-31
Active, closed
Janssen Research & Development, LLC
Phase 3
84
Barakaldo, Barcelona, Madrid, Málaga, Seville
2018-10-29
Active, closed
AstraZeneca
Phase 1
396
Barcelona, Madrid, Seville, Valencia
2018-10-11
Active, closed
AstraZeneca
Phase 3
730
Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Barcelona, Lugo, Madrid, Málaga, Santander, Seville
2018-09-27
Active, closed
Hoffmann-La Roche
Phase 1/2
422
Barcelona, Cáceres, Madrid, Seville
2018-09-25
Recruiting
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
DrugDaromun
Philogen S.p.A.
Phase 3
186
Badalona, Barcelona, Las Palmas de Gran Canaria, Donostia / San Sebastian, Madrid, Málaga, Murcia, Seville
2018-09-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Donostia / San Sebastian, Valencia, Barcelona, Madrid, Seville
2018-09-12
Active, closed
Hoffmann-La Roche
Phase 3
257
Barcelona, Madrid, Seville, Valencia
2018-08-16
Active, closed
AstraZeneca
Phase 3
216
Barcelona, Madrid, Málaga, San Sebastián, Seville, Valencia
2018-07-19
Active, closed
Myocardial FIbrosis in Repaired Tetralogy of FAllot- FIFA Study)
NCT04737135Congenital Heart Disease, Congenital Heart Defect, Fallot Tetralogy
Hospital Universitari Vall d'Hebron Research Institute
Observational
224
Madrid, Barcelona, Seville, Valencia
2018-07-09
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Badalona, Ávila, Alcorcón, Barcelona, Burgos, Madrid, Murcia, Seville
2018-06-21
Active, closed
Memorial Sloan Kettering Cancer Center
Phase 3
732
Oviedo, Madrid, Barcelona, Castellon, Seville, Valencia
2018-06-19
Recruiting
BioInvent International AB
Phase 1/2
140
Badalona, Barcelona, Madrid, Murcia, Seville
2018-05-16
Active, closed
Corcept Therapeutics
Phase 2
125
Alicante, Girona, Madrid, Málaga, Seville
2018-05-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Badalona, L'Hospitalet de Llobregat, Girona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville
2018-04-24
Active, closed
Bristol-Myers Squibb
Phase 3
545
Barcelona, Córdoba, Donostia / San Sebastian, Madrid, Pamplona, Sabadell (Barcelona), Seville, Valencia
2018-04-18
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Barcelona, Madrid, Pamplona, Salamanca, Seville
2018-04-17
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Córdoba, Ferrol, Girona, Huelva, Madrid, Oviedo, Pontevedra, Seville
2018-04-13
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
A Coruña, Barcelona, Madrid, San Sabastian Gipuzkoa, Seville
2018-04-11
By invitation
USWM CT, LLC
Phase 1
250
Seville
2018-04-09
Active, closed
Y-mAbs Therapeutics
Phase 2
122
Barcelona, Madrid, Seville, Valencia
2018-04-03
Recruiting
Hoffmann-La Roche
Phase 1/2
1,132
Seville, Barcelona, Madrid
2018-03-30
Rows per page Showing 501–1000 of 1054
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/seville?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,054 of those studies with a site in Seville.

How many clinical trials are recruiting in Seville?

491 of the 1,054 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 36 have not yet opened recruitment, 508 are active but closed to new participants, and 19 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.